Mon panier

Monoclonal Anti-DENV 2(strain Thailand/16681/1984)-NS1 Antibody, Human IgG1 (7E12) (MALS verified)

Avis des utilisateurs
Numéro de produit/spécification
Prix
Qté
DE1-M756-100ug
$415.00
DE1-M756-1mg
$2735.00
ETA of in-stock products:2 business days
Total des articles Montant du produit$ 0

Détails du produit

  • Source

    Monoclonal Anti-DENV 2(strain Thailand/16681/1984)-NS1 Antibody, Human IgG1 (7E12) is a recombinant chimeric monoclonal antibody expressed in HEK293, which combines the variable region of a mouse monoclonal antibody with human constant domain.

  • Antibody Type

    Recombinant Monoclonal

  • Clone

    7E12

  • Isotype

    Human IgG1, Kappa

  • Host Species

    Mouse

  • Specificity

    This product is a specific antibody specifically reacts with NS1.

  • Application

    Application
    Recommended Usage
    Western Blot
    0.1-10 ug/mL
    ELISA
    0.2-2 μg/mL
  • Purification

    Protein A purified / Protein G purified.

  • Aggregation

    Less than 10%, as determined by SEC-MALS.

  • Concentration

    Please refer to the Certificate of Analysis (CoA).

  • Form

    Lyophilized

  • Formulation

    Lyophilized from a 0.22 μm-filtered solution in PBS (pH 7.4), with trehalose as protectant.

    Please contact us for customized product forms or formulations.

  • Reconstitution

    Please refer to the Certificate of Analysis (CoA) for specific instructions.

  • Shipping

    Lyophilized product is shipped at ambient temperature.

  • Storage

    For long term storage, the product should be stored in a lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 12 months in lyophilized state;
    2. -70°C for 3 months under sterile conditions after reconstitution.
  • Notices

    Product Specific Notices: For research use only.

  • ACRO Quality Management System

    1. QMS(ISO, GMP)
    2. Quality Advantages
    3. Quality Control Process

Les clients ont également consulté

Affichage des données

  • Bioactivity-ELISA

     Non-structural protein 1/NS1 (DENV) ELISA

    Immobilized DENV2 (strain Thailand/16681/1984) NS1 protein, His Tag (Cat. No. NS1-D52H3) at 1 μg/mL (100 μL/well) can bind Monoclonal Anti-DENV 2(strain Thailand/16681/1984)-NS1 Antibody, Human IgG1 (7E12) (Cat. No. DE1-M756) with a linear range of 0.06-2 ng/mL (QC tested).

    Protocol
  • Bioactivity-SPR

     Non-structural protein 1/NS1 (DENV) SPR

    Monoclonal Anti-DENV 2(strain Thailand/16681/1984)-NS1 Antibody, Human IgG1 (7E12) (Cat. No. DE1-M756) captured on Protein A Chip can bind DENV2 (strain Thailand/16681/1984) NS1 protein, His Tag (Cat. No. NS1-D52H3) with an affinity constant of 0.167 nM as determined in a SPR assay (Biacore 8K) (Routinely tested).

    Protocol
  • Western Blot

     Non-structural protein 1/NS1 (DENV) WESTERN BLOT
  • Detection of Anti-DENV 2(strain Thailand/16681/1984)-NS1-7E12,Human,Human IgG1 | Human Kappa,HEK by Western Blot. Anti-DENV 2(strain Thailand/16681/1984)-NS1-7E12,Human,Human IgG1 | Human Kappa,HEK at 1/5000 dilution + DENV2 (strain Thailand/16681/1984) NS1 protein, His Tag (MALS verified) at 200ng.
    Secondary Antibody: (HFC)-HRP Goat Anti-Human IgG,Fcγ fragment specific (min X Bov,Hrs,Ms Sr Prot) at 1/2000 dilution.
    Predicted band size: 45~55 kDa 12% Bis-Tris Protein Gel.

Avis des utilisateurs
Publier un commentaire

Introduction de fond

Dengue is a mosquito-borne viral disease widely spread all over the world transmitted by 4 serotypes of dengue virus (DENV). The symptoms range from mild dengue fever to dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS) with high mortality. Currently, most of the studies on DENV vaccines emphasize on its envelope protein (i.e., Sanofi’s tetravalent dengue vaccine Dengvaxia). However, the fact pointing out that the vaccines with Envelope protein may could have negative effect on people never infected by DENV which makes the non-structural protein NS1 become another great target for vaccine research with its ability to avoid Antibody Dependent Enhancement.

Progrès de frontière

 
Drug Candidate Licensing
More
  • Informations de base sur le produit
  • Détails du produit
  • Les clients ont également consulté
  • Affichage des données
  • Avis des utilisateurs
  • Contexte